ClinicalTrials.gg

Hidradenitis Suppurativa clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 285 studies for Hidradenitis Suppurativa across more than 10 countries. 88 are recruiting or about to start. 247 of them are mainly about Hidradenitis Suppurativa (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
127
Recruiting
61
Active, not recruiting
25
Not yet recruiting
23
Terminated
21
Status unknown
13

Phase

Phase 2
91
Phase 3
33
Phase 1
24
Phase 4
11
Early Phase 1
10

Where

United States
161
Canada
66
Germany
65
France
53
Spain
50
Poland
45

Who develops what

Add Hidradenitis Suppurativa to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 26 programs from 22 companies, 26 with this as their studies’ main aim; 6 with a live phase 3 study; 16 primary completions in the next 12 months. Compare Almirall, Incyte and Novartis here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AdalimumabRecent, repeated
Evidence
  • NCT07151937 · Almirall, S.A. · Phase 2 · live · background · “Adalimumab” · registered Sep 2025
  • NCT05322473 · MoonLake Immunotherapeutics AG · Phase 2 · comparator · “Adalimumab” · registered Apr 2022
  • NCT04988308 · Johnson & Johnson · Phase 2 · comparator · “Adalimumab” · registered Jul 2021
  • NCT03248531 · UCB S.A. · Phase 2 · comparator · “Adalimumab” · registered Aug 2017
Abbott41% of its industry studiesUS: Amgen (FDA 2016) + 3 othersEU: AbbVie (EMA 2003) + 10 others22 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
bimekizumabApproved: US 2023 · EU 2021☆ Track1 live phase-3 study: NCT06921850UCB S.A.
povorcitinib☆ Track2 live phase-3 studies: NCT06855498, NCT06212999Incyte Corporation
remibrutinibApproved: US 2025 · EU 2026☆ Track3 live phase-3 studies: NCT07665437, NCT06799000, NCT06840392Novartis
BFB759☆ Track1 live phase-3 study: NCT07287644Bluefin Biomedicine, Inc.
sonelokimab☆ Track1 live phase-3 study: NCT07007637MoonLake Immunotherapeutics AG

The 5 in phase 3 with the nearest primary completion, of 26 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (16)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 8 Dec 2026 est.ritlecitinib · Pfizer · Phase 2 main aimNCT07228390 A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. — primary endpoint: Difference in proportion of responders based on Hidradenitis Suppurativa Clinical Response achieving at least 50% reduction from baseline (Hidradenitis Suppurativa Clinical Response HiSCR50) in patients with HS treated with ritlecitinib versus placebo. · 128 enrolled
  • 21 Dec 2026 est.bimekizumab · UCB S.A. · Phase 3 main aimNCT06921850 A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa — primary endpoint: Geometric Mean Plasma bimekizumab concentrations at Week 16 · 43 enrolled
  • 26 Dec 2026 est.povorcitinib · Incyte Corporation · Phase 3 main aimNCT06212999 A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa — primary endpoint: Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) · 617 enrolled

13 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hidradenitis Suppurativa studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 6 open · JAK inhibitors 3 open

Coming up

40studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger. 13 (21%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 12 (20%) take healthy volunteers.

Recruiting studies that take each age, of 61
AgeWomenMen
107 (11%)7 (11%)
1860 (98%)59 (97%)
3060 (98%)59 (97%)
4060 (98%)59 (97%)
5059 (97%)58 (95%)
6557 (93%)56 (92%)
7551 (84%)50 (82%)
8541 (67%)40 (66%)

Across all 285 studies, recruiting or not: 26% stop at 75 or younger and 13% at 65; 18% take children; 2% are for women only and 0% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hidradenitis Suppurativa studies take

Of 54 phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 117 mo11–29 · 20 studies——
Phase 215 mo11–24 · 54 studies15 mo10–23 · 44 studies—
Phase 325 mo20–38 · 26 studies——
Interventional, no phase17 mo11–31 · 25 studies——
Observational34 mo25–… · 44 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 285. Browse all 285 → or search them.